

**ATTACHMENT A**

**SCHEDULE OF DOCUMENTS - FOI-3026**

<b>Document no.</b>	<b>Date</b>	<b>Number of pages</b>	<b>Description</b>	<b>Decision on access<sup>1</sup></b>	<b>Exemption</b>
1	10 July 2021	2	Attendee informal notes from meeting	REI	Section 47C (part) Section 47F (part) Section 47G (part)

---

<sup>1</sup> E = Exempt, R = Release, RI = Release with irrelevant information removed, RE = Release with exempt information removed.

Meeting with Pfizer – 10 July

Want to have discussions to move as quickly as possible – commercially sensitive.

What Pfizer has been doing partnership with Biotech

Able to provide further info on pricing principles, vaccine development etc.

s 47F - senior legal director to answer questions about the legal documents.

Supplies to the NIP.

Working to reg authorities to test and manufacture mRNA vaccines.

Could deploy at unprecedented speed.

Up scaling manufacturing and distribution strategies.

Want to consider how we can invest while they progress manufacturing and clinical development.

Want to understand priority population. Front line health workers, elderly and immune compromised.

Products in the vaccine space

Clinical trials . Gov

Studies Pfizer and biotech are conducting

3 mRNA platforms and candidates

Looking at dose level and schedules.

Rest of Pfizer

Ongoing work.

Viral work inhibitors.

Other work too.

Studies conducted in Germany and the US – 4 May first subject vaccinated in the US and Germany in April.

Phase 1/2 being developed – dose finding and candidate selection in healthy adults.

Manufacturing sites across a number of countries that could be used for full scale production. Not in one country or site.

Also looking at distortion approach across the globe.

Supply chains – any risks to getting the materials needed?

Feeling confident.

Possibly s 47C, s 47G by the end of this year,

1.2 billion doses by the end of 2021.

TGA, FDA, EMA.

Use NIP infrastructure to support efficiency and speed to support distribution processes.

ATAGI role in the assessment process.

Engagement – should they go directly to TGA or should also go to ATAGI.

ATAGI will continue to provide role in terms of regulation but provides policy role.

NIP mechanism to support distortion, workforce capacity building, safety and surveillance and working with states and territories.

ACV – provides advice to TGA.

Engaging with Gavi COVAX.

s 47C

Regulatory processes – is there emergency consideration?

s 47F – non disclosure agreement – to send contact details.

THIS DOCUMENT HAS BEEN RELEASED UNDER  
THE FREEDOM OF INFORMATION ACT 1982 (C/TH)  
BY THE DEPARTMENT OF HEALTH